During the COVID-19 pandemic, laptops and web-based programs kept students connected to school. Now, parents are asking the ...

Jace’s interest in marine biology may stem from his frequent visits to the Da Vinci Science Center, just down the street from ...

As more districts throughout Texas face state intervention, here's what's been lost and gained in Houston ISD in the three ...

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

"For patients willing to use them several times per week for months, at-home RF and microcurrent devices can provide modest ...

Triple oral metronomic chemotherapy combined with ultra-low-dose immunotherapy (TMC-I) may be a promising first-line ...

ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once ...

The president met with aides for two hours at the White House about a possible cease-fire extension, according to a senior administration official. Earlier, Mr. Trump had suggested in a social media ...

BioInvent International AB (publ) ( BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors May 27, 2026 8:00 AM EDT Good morning, and welcome to the BioInvent ...

Zoci Intracranial ORR -- Achieved a 62.5% confirmed intracranial overall response rate and nearly 69% best overall ...

(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Weekly AHB-137 300 mg for 16 weeks achieved HBV DNA <10 IU/mL in 100% and complete response in 68% at end of treatment without concomitant nucleos(t)ide analogues. Baseline HBsAg stratified outcomes, ...